AXSM Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Axsome Therapeutics, Inc. (AXSM)Business Wire • 05/20/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) InvestorsBusiness Wire • 05/20/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) InvestorsBusiness Wire • 05/19/22
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Investors to Contact the FirmBusiness Wire • 05/19/22
AXSOME THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Axsome Therapeutics, PRNewsWire • 05/19/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of InvestorsBusiness Wire • 05/18/22
Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of PsychiatryPRNewsWire • 05/18/22
Shareholder Alert: Did You Purchase Shares of Axsome Therapeutics, Inc. (AXSM)? Robbins LLP Alerts Investors of Class Action Against Axsome Therapeutics, Inc.Business Wire • 05/18/22
AXSOME ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 05/18/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of InvestorsBusiness Wire • 05/17/22
The Law Offices of Frank R. Cruz Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of InvestorsBusiness Wire • 05/17/22
SHAREHOLDER ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSMPRNewsWire • 05/17/22
AXSOME THERAPEUTICS, INC. (AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)Newsfile Corp • 05/17/22
INVESTOR ALERT: Axsome Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AXSMBusiness Wire • 05/16/22
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. With Losses of $500,000 to Contact the FirmBusiness Wire • 05/16/22
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. (NASDAQ: AXSM)PRNewsWire • 05/16/22
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AXSMBusiness Wire • 05/16/22
Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness MonthPRNewsWire • 05/16/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSMNewsfile Corp • 05/09/22
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep ApneaGlobeNewsWire • 05/09/22
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome TherapeuticsPRNewsWire • 05/09/22
